The Hartford County Maryland Health Department is making the path to Opioid Use Disorder (OUD) recovery more attainable for local patients. The first step, providing patients access to the Sparrow Therapy System to overcome withdrawal symptoms. 

Ending opioid addiction in the Lowcountry is the goal of the Medical University of South Carolina staff as they get ready to launch a multi-year clinical trial to test a new device aimed at helping patients with opioid withdrawals.

Collaborative study awarded to the University of Texas Medical Branch, Medical University of South Carolina, and Spark Biomedical

Spark Biomedical creates a subsidiary, Five Liters, to focus the initiative while taking advantage of the company’s experience in turning patents into FDA-approved products.

The companies partnered to design, develop and manufacture the medical device technology that provides a wearable neurostimulation solution for opioid withdrawal relief

The jointly run pilot clinical study is the first step in pioneering closed-loop opioid withdrawal detection and treatment 

Battelle announced today that it entered into a collaborative agreement with Spark Biomedical to jointly run a pilot clinical study. Through the joint study, the two companies aim to advance the remote detection and treatment of opioid use disorder (OUD) using wearable biosensors.

A clinical trial in Dallas will test new technology that could help infants overcome withdrawal from exposure to opioids while in the womb.

Spark Biomedical created the FDA-approved Sparrow Therapy System. It’s essentially an earpiece that sends mild electrical pulses to the brain to help alleviate the withdrawal symptoms that patients go through while they’re detoxing, like insomnia, tremors, chills and sweating, bone pain, mood swings, and more.

The Medical University of South Carolina and UT Southwestern Medical Center join Spark Biomedical in Phase II clinical trial.